424 related articles for article (PubMed ID: 12584227)
1. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
van Nunen AB; Hansen BE; Suh DJ; Löhr HF; Chemello L; Fontaine H; Heathcote J; Song BC; Janssen HL; de Man RA; Schalm SW
Gut; 2003 Mar; 52(3):420-4. PubMed ID: 12584227
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
3. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
Guptan RC; Thakur V; Kazim SN; Sarin SK
J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
[TBL] [Abstract][Full Text] [Related]
5. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
7. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
[TBL] [Abstract][Full Text] [Related]
8. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
9. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
Chien RN; Liaw YF; Atkins M
Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.
Yoon SK; Jang JW; Kim CW; Bae SH; Choi JY; Choi SW; Lee YS; Lee CD; Chung KW; Sun HS; Kim BS
Intervirology; 2005; 48(6):341-9. PubMed ID: 16024938
[TBL] [Abstract][Full Text] [Related]
12. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
[TBL] [Abstract][Full Text] [Related]
14. Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection.
Hom X; Little NR; Gardner SD; Jonas MM
Pediatr Infect Dis J; 2004 May; 23(5):441-5. PubMed ID: 15131468
[TBL] [Abstract][Full Text] [Related]
15. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
[No Abstract] [Full Text] [Related]
16. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.
Lee HC; Suh DJ; Ryu SH; Kim H; Shin JW; Lim YS; Chung YH; Lee YS
Gut; 2003 Dec; 52(12):1779-83. PubMed ID: 14633962
[TBL] [Abstract][Full Text] [Related]
17. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
18. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
[TBL] [Abstract][Full Text] [Related]
19. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation.
Lee CM; Ong GY; Lu SN; Wang JH; Liao CA; Tung HD; Chen TM; Changchien CS
J Hepatol; 2002 Nov; 37(5):669-74. PubMed ID: 12399235
[TBL] [Abstract][Full Text] [Related]
20. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
